Global Disclosure
Statement

Novavax places the utmost value on maintaining the integrity of its relationships with healthcare professionals and organizations, which we believe is critical to driving the development of next innovative therapies and medicine, advancing patient care, and improving public health. Every engagement is grounded in a genuine need to further medical knowledge, support research, or improve patient outcomes, and no payments are made to healthcare professionals as an inducement.

We believe in promoting full transparency regarding the financial relationships we maintain with healthcare professionals, healthcare organizations, and patient advocacy organizations, and we honor all global transparency requirements. In doing so, we diligently record all transfers of value to healthcare professionals and organizations, and we report pursuant to all the applicable laws, regulations, and codes of conduct governing the transparency of these interactions to ensure public trust and confidence.

We publicly disclose the transfers of value through applicable government portals and the Novavax website.

In the United States, our data is publicly accessible via the Centers for Medicare and Medicaid Services Open Payments Program in accordance with the Physician Payments Sunshine Act. You can access their website here.

In the European Union, we are a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Vaccines Europe, and endorse the EFPIA Disclosure Code, a set of guiding principles that requires pharmaceutical companies to publicly disclose transfers of value made to European healthcare professionals and healthcare organizations. Select from the EFPIA countries below for more information.